Eyepoint Pharmaceuticals (EYPT) Scheduled to Post Earnings on Tuesday

Eyepoint Pharmaceuticals (NASDAQ:EYPT) is set to release its earnings data before the market opens on Tuesday, November 6th. Analysts expect Eyepoint Pharmaceuticals to post earnings of ($0.13) per share for the quarter.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last announced its quarterly earnings data on Wednesday, September 12th. The company reported ($0.19) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.08). The business had revenue of $0.72 million during the quarter, compared to analysts’ expectations of $0.67 million. Eyepoint Pharmaceuticals had a negative return on equity of 301.45% and a negative net margin of 1,795.71%. On average, analysts expect Eyepoint Pharmaceuticals to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

EYPT traded up $0.06 during midday trading on Wednesday, reaching $2.20. The company’s stock had a trading volume of 1,008 shares, compared to its average volume of 834,991. The stock has a market cap of $119.95 million, a PE ratio of -3.79 and a beta of 0.85. The company has a debt-to-equity ratio of 1.48, a quick ratio of 1.84 and a current ratio of 1.84. Eyepoint Pharmaceuticals has a 1 year low of $0.93 and a 1 year high of $3.94.

A number of brokerages have weighed in on EYPT. ValuEngine upgraded shares of Eyepoint Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday. HC Wainwright set a $3.00 price objective on shares of Eyepoint Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, July 27th. Zacks Investment Research cut shares of Eyepoint Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, July 10th. Finally, B. Riley increased their price target on shares of Eyepoint Pharmaceuticals from $5.00 to $6.00 and gave the company a “buy” rating in a report on Tuesday, October 16th. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $5.40.

Eyepoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a specialty biopharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases. The company's lead product is ILUVIEN for the treatment of diabetic macular edema; and product candidate is YUTIQ, a non-erodible fluocinolone acetonide insert for the treatment of non-infectious posterior uveitis that is in the Phase III clinical trials.

Featured Article: Asset Allocation

Earnings History for Eyepoint Pharmaceuticals (NASDAQ:EYPT)

Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply